Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 15, 2016	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	10,429	$380.09	686,571
Dec 03, 2009	YANCOPOULOS GEORGE Director, EVP CSO & Pres Regn Res Labs	Director, EVP CSO & Pres Regn Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	100,000	$8.77	688,235
Dec 15, 2016	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	195,079	$20.32	697,000
Mar 09, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	150,000	$30.63	713,990
Dec 30, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	130,714	$483.25	750,224
May 01, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Other acquisition or disposition	--	--	752,486
Jan 04, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Other acquisition or disposition	--	--	752,486
Dec 11, 2023	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	12,841	$844.09	752,486
Feb 19, 2019	YANCOPOULOS GEORGE Director, President and CSO	Director, President and CSO	Form 4	Bona fide gift	150,722	--	753,316
Dec 11, 2023	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	25,155	--	765,327

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media